CARVYKTI® (ciltacabtagene autoleucel) logo
  • About CARVYKTI®
    How CARVYKTI® works
    Manufacturing CARVYKTI®
  • Cartitude-4 Efficacy
    Primary Analysis
    Study Design
    Progression-Free Survival (PFS)
    Overall Survival (OS)
    Depth of Response
    Duration of Response
    Follow-Up Analysis
    Progression-Free Survival (PFS)
    Overall Survival (OS)
    Depth of Response
    Duration of Response
  • CARVYKTI® Safety
    Boxed Warning
    Cytokine Release
    Syndrome (CRS)
    Neurologic Toxicities
    Hemophagocytic
    Lymphohistiocytosis (HLH)
    Prolonged and/or
    Recurrent Cytopenias
    Secondary Malignancies
    Additional Warnings & Precautions, and ARs ≥10%
    Long-Term Safety
  • TREATMENT PROCESS
    Patient Eligibility
    Steps in the Treatment Process
  • Resources
    For Physicians
    For Nurses/APPs
    For Patients/Care Partners
    Patient Support Program
    For Access and Reimbursement Support
    For Order Management
  • Additional Trials
    Cartitude-1 Efficacy
    Study Design
    Depth of Response
    Duration of Response
    Survival Rates
    Time to Response
  • Unmet Need
  • Treatment Centers
  • Coverage Lookup
  • Get In Touch
  • CARVYKTI® Prescribing Information
  • CARVYKTI® REMS
  • Contact Us
  • Go To Patient Website
  • Prescribing Information
    CARVYKTI® PRESCRIBING INFORMATION
    CARVYKTI® LA INFORMACIÓN DE PRESCRIPCIÓN
  • CARVYKTI® REMS
  • Get In Touch
  • Contact Us
  • For US Healthcare Professionals
  • Go To Patient Website
Treatment CentersCoverage Lookup

Cookie Policy

Loading HTML...
GET IN
TOUCH
SCROLL TO TOP ↑